Acumen Pharmaceuticals Inc
ABOS
NASDAQ
Biotechnology
$2.67
USD
+0.12 (+4.71%)
At close: Aug 14, 2026, 4:00 PM EDT
Market Cap $184.18M
Volume 525.8K
Revenue
$0
TTM
— YoY
Gross Margin
—
TTM
— YoY
Net Income
$-105.04M
TTM
+23.1%
YoY
Operating Cash Flow
$-91.79M
TTM
+22.1%
YoY
Revenue & Net Income
USD Millions
Margins Trend
Percent of revenue
Income Statement Detail
USD Millions, except per-share and share count figures
Metric | Q2 2025 | Q3 2025 | Q4 2025 | Q1 2026 | Q2 2026 |
|---|---|---|---|---|---|
Revenue | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
YoY Growth | — | — | — | — | — |
Cost of Revenue | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
Gross Profit | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
Selling, General & Administrative | 4.6 | 4.5 | 4.7 | 4.7 | 4.7 |
Other Operating Expenses | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
Total Operating Expenses | 41.8 | 26.5 | 25.2 | 21.1 | 32.6 |
Operating Income | -41.8 | -26.5 | -25.2 | -21.1 | -32.6 |
EBITDA | -41.7 | -26.5 | -25.2 | -21.1 | -32.5 |
Other Income / Expense | -0.2 | -0.5 | -0.2 | 0.4 | -0.2 |
Total Other Income / Expense | 0.8 | 0.1 | 0.1 | 0.4 | -0.2 |
Income Before Income Taxes | -41.0 | -26.5 | -25.1 | -20.7 | -32.7 |
Income Taxes | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
Net Income | -41.0 | -26.5 | -25.1 | -20.7 | -32.7 |
Consolidated Net Income / Loss | -41.0 | -26.5 | -25.1 | -20.7 | -32.7 |
Net Income Attributable to Common Shareholders | -41.0 | -26.5 | -25.1 | -20.7 | -32.7 |
Basic EPS | -$0.68 | -$0.44 | -$0.41 | -$0.33 | -$0.45 |
Diluted EPS | -$0.68 | -$0.44 | -$0.41 | -$0.33 | -$0.45 |
Basic Shares Outstanding | 60.6M | 60.6M | 60.6M | 63.2M | 72.3M |
Diluted Shares Outstanding | 60.6M | 60.6M | 60.6M | 63.2M | 72.3M |